Galectin-3 and acute heart failure: genetic polymorphisms, plasma level, myocardial fibrosis and 1-year outcomes

Biomark Med. 2020 Jul;14(11):943-954. doi: 10.2217/bmm-2020-0269.

Abstract

Aim: This study sought to investigate the relationship between galectin-3 (Gal-3), myocardial fibrosis (MF) and outcomes in acute heart failure. Materials & methods: The single-nucleotide polymorphisms (SNPs) of LGALS3 at rs4644 and rs4652, plasma Gal-3 level, MF and major adverse events (MAEs) were obtained. Results: There was no significant difference in MAEs when categorizing patients by the LGALS3 SNPs at rs4644 and rs4652. The circulating Gal-3 was related to the degree of MF (p < 0.001). Plasma Gal-3 level and MF can predict an increased risk of MAEs (p < 0.001, p = 0.023, respectively). Conclusion: Not the SNPs of LGALS3 but Gal-3 and MF can predict MAEs in acute heart failure at 1 year of follow-up.

Keywords: acute heart failure; galectin-3; major adverse event; myocardial fibrosis; polymorphism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Proteins / genetics*
  • Female
  • Fibrosis
  • Galectins / blood*
  • Galectins / genetics*
  • Genetic Predisposition to Disease / genetics
  • Heart Failure / blood
  • Heart Failure / genetics*
  • Heart Failure / pathology*
  • Humans
  • Male
  • Middle Aged
  • Myocardium / pathology*
  • Polymorphism, Single Nucleotide*
  • Prognosis

Substances

  • Blood Proteins
  • Galectins
  • LGALS3 protein, human